Skip to content

Capricor Therapeutics CAPR Government grants

Government grants at other companies

Addus HomeCare logo
Addus HomeCareADUS
$14.64M+68.2%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$6.34M
Amprius Technologies logo
Amprius TechnologiesAMPX
$2.74M
ICU Medical logo
ICU MedicalICUI
$4.77M-30.2%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$176.11M+12.0%
Micron Technology logo
Micron TechnologyMU
$1B+19.9%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%
Enterprise value$1.62B+308%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GovernmentAssistanceLiabilityCurrent.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's government grants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's government grants?
Capricor Therapeutics (CAPR) reported government grants of $6.34M in Q1 2026.
What does government grants mean?
This represents the current portion of government assistance or grant funding received in advance of fulfilling specific performance obligations or research milestones. It functions as a deferred revenue account that will be recognized as income once the associated research activities or conditions are satisfied. Monitoring this liability helps investors understand the company's near-term obligations to grant-issuing bodies.